Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04140162
Title Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Rogel Cancer Center
Indications

multiple myeloma

Therapies

Lenalidomide

Bortezomib + Daratumumab + Dexamethasone + Lenalidomide

Daratumumab + Dexamethasone + Lenalidomide

Daratumumab + Lenalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.